Get the Stockscreener App
9.97
0.50%
0.05
After Hours:
10.00
0.03
+0.30%
Biocryst Pharmaceuticals Inc stock is traded at $9.97, with a volume of 5.80M.
It is up +0.50% in the last 24 hours and up +47.27% over the past month.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
See More
Previous Close:
$9.92
Open:
$9.93
24h Volume:
5.80M
Relative Volume:
1.38
Market Cap:
$1.87B
Revenue:
$331.41M
Net Income/Loss:
$-226.54M
P/E Ratio:
-8.4492
EPS:
-1.18
Net Cash Flow:
$-97.31M
1W Performance:
+11.65%
1M Performance:
+47.27%
6M Performance:
+28.15%
1Y Performance:
+86.70%
1-Day Range:
$9.90
$10.39
1-Week Range:
$9.59
$11.11
52-Week Range:
$5.23
$11.11
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Name
Biocryst Pharmaceuticals Inc
Sector
Phone
919-859-1302
Address
4505 EMPEROR BOULEVARD, DURHAM, NC
Compare BCRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
9.97 | 1.87B | 331.41M | -226.54M | -97.31M | -1.18 |
|
ZTS
Zoetis Inc
|
159.27 | 70.23B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.74 | 48.23B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.36 | 48.22B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.93 | 18.57B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
301.42 | 13.29B | 2.76B | 1.11B | 898.10M | 22.77 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-25 | Initiated | Wedbush | Outperform |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Sep-18-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Aug-04-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-13-23 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-22-23 | Upgrade | Needham | Hold → Buy |
| Nov-02-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-05-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-05-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-18-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-11-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-10-21 | Initiated | Oppenheimer | Outperform |
| Aug-06-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-03-21 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-01-21 | Initiated | Cowen | Outperform |
| Sep-29-20 | Resumed | JP Morgan | Overweight |
| Jun-17-20 | Initiated | BTIG Research | Neutral |
| May-05-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-15-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| May-24-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-16-18 | Resumed | Piper Jaffray | Overweight |
| Aug-08-18 | Resumed | JP Morgan | Overweight |
| Jul-17-18 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Jun-22-18 | Initiated | Seaport Global Securities | Neutral |
| Jan-02-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Dec-20-17 | Initiated | Barclays | Equal Weight |
| Sep-15-17 | Initiated | RBC Capital Mkts | Sector Perform |
| Sep-06-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-06-17 | Upgrade | Jefferies | Hold → Buy |
| Feb-16-17 | Initiated | Ladenburg Thalmann | Buy |
| Aug-12-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-04-16 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-09-16 | Reiterated | FBR Capital | Outperform |
| Feb-09-16 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-09-16 | Downgrade | Needham | Buy → Hold |
View All
Biocryst Pharmaceuticals Inc Stock (BCRX) Latest News
Best Momentum Stocks to Buy for May 9th - Yahoo Finance
Mariner LLC Buys 3,224 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World
BioCryst targets $1B in global ORLADEYO revenue by 2029 amid 33-37% projected growth this year - MSN
Why BioCryst (BCRX) Might be Well Poised for a Surge - Yahoo Finance
What Makes BioCryst Pharmaceuticals (BCRX) a Strong Momentum Stock: Buy Now? - Yahoo Finance
BioCryst at Citizens JMP: Orlodayo’s Market Growth and Pipeline Prospects - Investing.com
BioCryst at Citizens JMP: Orlodayo’s Market Growth and Pipeline Prospects By Investing.com - Investing.com UK
Does BioCryst (BCRX) Have the Potential to Rally 61.21% as Wall Street Analysts Expect? - Yahoo Finance
Biocryst seeks FDA OK of Orladeyo for HAE patients as young as 2 - Angioedema News
Analysts Are Upgrading BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) After Its Latest Results - Yahoo Finance
Barclays Raises BioCryst Pharma (BCRX) Price Target to $11 | BCR - GuruFocus
Barclays Raises BioCryst Pharma (BCRX) Price Target to $11 | BCRX Stock News - GuruFocus
Barclays Raises Price Target for BioCryst (BCRX), Highlights Growth Prospects | BCRX Stock News - GuruFocus
BioCryst Pharmaceuticals (BCRX) Reports Break-Even Earnings for Q1 - MSN
BioCryst Pharmaceuticals’ SWOT analysis: stock outlook amid HAE market growth - Investing.com Nigeria
BioCryst Pharma (BCRX) Sees Price Target Boost from RBC Capital | BCRX Stock News - GuruFocus
BioCryst Pharma (BCRX) Price Target Raised by JP Morgan | BCRX Stock News - GuruFocus
BCRX Price Target Raised as BioCryst Shows Strong Fundamentals | - GuruFocus
BioCryst Pharma (BCRX) Maintains Buy Rating with $30 Price Targe - GuruFocus
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q1 2025 Earnings Call Transcript - Insider Monkey
RBC Raises Price Target on BioCryst Pharmaceuticals to $13 From $11, Keeps Outperform Rating - marketscreener.com
BCRX Stock: BioCryst's Price Target Raised with Positive Revenue - GuruFocus
When (BCRX) Moves Investors should Listen - news.stocktradersdaily.com
Why These 10 Firms Soared on Monday - Insider Monkey
BCRX: Needham Raises Price Target for BioCryst Pharma to $17 | B - GuruFocus
Why BioCryst Pharmaceuticals, Inc. (BCRX) Soared on Monday - Yahoo Finance
BioCryst stock target to $14 on Orladeyo sales, maintains Buy By Investing.com - Investing.com Nigeria
BioCryst Pharmaceuticals Inc (BCRX) Q1 2025 Earnings Call Highlights: Strong ORLADEYO Sales ... - Yahoo Finance
BioCryst Pharmaceuticals Inc (BCRX) Q1 2025 Earnings Call Highli - GuruFocus
Earnings call transcript: BioCryst’s Q1 2025 revenue and stock surge By Investing.com - Investing.com Nigeria
BioCryst (BCRX) Surges with ORLADEYO Revenue and Debt Reduction Efforts - GuruFocus
BioCryst Pharmaceuticals Reports Strong Q1 2025 Growth - TipRanks
BioCryst Shares Surge To 16-Month High On Strong Q1 Results: Retail Sentiment Turns Extremely Bullish - MSN
BioCryst Pharmaceuticals (BCRX) Boosts Revenue Guidance on Stron - GuruFocus
BioCryst Pharmaceuticals Soars 23% In One SessionHere's Why It Surprised Investors - Benzinga
BioCryst Pharmaceuticals (BCRX) Boosts Revenue Guidance on Strong ORLADEYO Sales - GuruFocus
Top Midday Gainers - marketscreener.com
BioCryst: Strong Opportunity For A Double With A Proven Therapy (BCRX) - Seeking Alpha
BioCryst Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Crude Oil Falls Over 2%; ISM Services PMI Rises In April - Benzinga
BioCryst Pharmaceuticals surges 2% on strong Q1 results, raised outlook By Investing.com - Investing.com Nigeria
BioCryst Pharmaceuticals (BCRX) Surges on Q1 Earnings Beat: What Traders Need to Know - RagingBull
BioCryst Pharmaceuticals (BCRX) Boosts Revenue Forecast Amid Strong Q1 Results - GuruFocus
BioCryst Pharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:BCRX) - Seeking Alpha
BioCryst stock jumps on raised guidance, strong Q1 report - Seeking Alpha
Napco Security Technologies Posts Better-Than-Expected Results, Joins Skechers, BioCryst Pharmaceuticals And Other Big Stocks Moving Higher On Monday - Benzinga
BioCryst Hikes on Q1 Figures - Baystreet.ca
Earnings call transcript: BioCryst’s Q1 2025 revenue and stock surge - Investing.com
BioCryst Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
BioCryst Q1 2025 slides: ORLADEYO sales surge, guidance raised By Investing.com - Investing.com Canada
BioCryst Pharma Stock Soars 10% Pre-Market On Upbeat Q1 Earnings, Improved Full Year Guidance: Retail’s Pleased - MSN
Biocryst Pharmaceuticals Inc Stock (BCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
1.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):